North Estonia Medical Centre: Difference between revisions

From Beacon
No edit summary
m (Update categories.)
 
(83 intermediate revisions by 7 users not shown)
Line 1: Line 1:
The North Estonia Medical Centre is one of the top healthcare providers in the country. Its statutes states that their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."  
<span style="display:none">forresearchers</span>
<!--
<span style="display:none">forpatients</span>
Source:
<span style="display:none">forproviders</span>
[https://www.regionaalhaigla.ee/en]
<span style="display:none">forpolicymakers</span>
-->
<span style="display:none">estoniacountry</span>
<span style="display:none">isCancerCenter</span>
[https://wiki.beaconcancer.org/index.php?title=Cancer_Centers Go back to Cancer Centers list.]
{{#set:
[[hasCoordinates::59.398689, 24.701547]]
}}
== [[hasClinicalTrial::Trials_(North_Estonia_Medical_Centre)|Trials]] ==
</div>


== [[hasExperts::Experts_(North_Estonia_Medical_Centre)|Experts]] ==
<div class="mw-collapsible" data-expandtext="Show" data-collapsetext="Hide">
</div>


== OECI Criteria Compliance ==
== Learning Resources ==
<div class="mw-collapsible" data-expandtext="Show" data-collapsetext="Hide">
=== [[hasTraining::Trainings:_Professional_Training_(North_Estonia_Medical_Centre)|Trainings: Professional Training]] ===
</div>


{| class="wikitable mw-collapsible"
== [[hasHospitalCapacityInfo::Novel_Therapies_and_Diagnostic_Methods_(North_Estonia_Medical_Centre)|Novel Therapies and Diagnostic Methods]] ==
|+ class="nowrap" | 5. Cooperation with universities
<div class="mw-collapsible" data-expandtext="Show" data-collapsetext="Hide">
|-
</div>
|
! scope="col" | CORE
! scope="col" | Compliance
|-
! scope="row" | 5.1. For training and postgraduate education activities.
| Yes || No
|-
! scope="row" | 5.2. For research activities.
| Yes || No
|}


== Cancer-related Patient Associations and Resources ==
<div class="mw-collapsible" data-expandtext="Show" data-collapsetext="Hide">


== [[Trials]] ==
=== [[hasPatientResource::Resource:_Learning_Resources_for_Relatives_and_Caretakers_(North_Estonia_Medical_Centre)|Resource: Learning Resources for Relatives and Caretakers]] ===


'''[https://clinicaltrials.gov/ct2/show/NCT03104699?cond=Cancer&locn=%22North+Estonia+Medical+Centre%22&cntry=EE&lupd_s=10%2F21%2F2022&lupd_d=14 Study of AGEN2034 in Advanced Tumors and Cervical Cancer]'''
=== [[hasPatientResource::Resource:_Trials_Information_for_Patients_(North_Estonia_Medical_Centre)|Resource: Trials Information for Patients]] ===


'''Summary:''' This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
=== [[Service:_Chemotherapy_Counseling_(North_Estonia_Medical_Centre)|Service: Chemotherapy Counseling]] ===


'''Sponsor, manager, or home institution:''' Agenus Inc.
=== [[hasPatientResource::Service:_Palliative_Care_Nurse_Advisor_(North_Estonia_Medical_Centre)|Service: Palliative Care Nurse Advisor]] ===


'''Intervention/Treatment:''' Drug: AGEN2034
=== [[hasPatientResource::Service:_Tobacco_Cessation_Counseling_Office_(North_Estonia_Medical_Centre)|Service: Tobacco Cessation Counseling Office]] ===
</div>


'''Number of patients:''' 211 participants
__NOTOC__
 
<span style="display:none">hasCoordinates::59.398689, 24.701547</span>
'''Beginning Date:''' April 7, 2017
<span style="display:none">hasClinicalTrial::Trials_(North_Estonia_Medical_Centre)|Trials</span>
 
<span style="display:none">hasExperts::Experts_(North_Estonia_Medical_Centre)|Experts</span>
'''Last Update:''' November 3, 2022
<span style="display:none">hasTraining::Trainings:_Professional_Training_(North_Estonia_Medical_Centre)|Trainings: Professional Training</span>
 
<span style="display:none">hasHospitalCapacityInfo::Novel_Therapies_and_Diagnostic_Methods_(North_Estonia_Medical_Centre)|Novel Therapies and Diagnostic Methods</span>
'''Recruitment Status:''' Completed.
<span style="display:none">hasPatientResource::Resource:_Learning_Resources_for_Relatives_and_Caretakers_(North_Estonia_Medical_Centre)|Resource: Learning Resources for Relatives and Caretakers</span>
 
<span style="display:none">hasPatientResource::Resource:_Trials_Information_for_Patients_(North_Estonia_Medical_Centre)|Resource: Trials Information for Patients</span>
'''Cancer areas of interest:''' Advanced Cancer and Cervical Cancer
<span style="display:none">hasPatientResource::Service:_Palliative_Care_Nurse_Advisor_(North_Estonia_Medical_Centre)|Service: Palliative Care Nurse Advisor</span>
 
<span style="display:none">hasPatientResource::Service:_Tobacco_Cessation_Counseling_Office_(North_Estonia_Medical_Centre)|Service: Tobacco Cessation Counseling Office</span>
'''[https://clinicaltrials.gov/ct2/show/NCT04241185?cond=Cancer&locn=%22North+Estonia+Medical+Centre%22&cntry=EE&lupd_s=10%2F21%2F2022&lupd_d=14 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)]'''
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
 
<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
'''Summary:''' This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.
<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
 
<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
'''Sponsor, manager, or home institution:''' Merck Sharp & Dohme LLC
<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
 
<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
'''Intervention/Treatment:''' Drug: Pembrolizumab;
<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
Radiation: Conventional Radiotherapy (Bladder only);
<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
Radiation: Conventional Radiotherapy (Bladder and pelvic nodes);
<span style="display:none">hasCancerType::C50: Breast cancer</span>
Radiation: Hypofractionated Radiotherapy (Bladder only);
<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
Drug: Cisplatin;
<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
Drug: Fluorouracil (5-FU);
<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
Drug: Mitomycin C (MMC);
<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
Drug: Gemcitabine;
<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
Drug: Placebo to Pembrolizumab
<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
 
<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
'''Number of patients:''' 636 participants
<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
 
<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
'''Beginning Date:''' January 27, 2020
<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
 
<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
'''Last Update:''' October 21, 2022
<span style="display:none">hasCancerType::unknown</span>
 
'''Recruitment Status:''' Recruiting.
 
'''Cancer areas of interest:''' Urinary Bladder Neoplasms
 
== [[Experts]] ==
 
* '''[https://www.regionaalhaigla.ee/en/chemotherapy Chemotherapy Centre]'''
 
* '''[https://www.regionaalhaigla.ee/en/haematology Haematology Centre]'''
 
* '''[https://www.regionaalhaigla.ee/en/oncology-and-haematology-policlinic Oncology and Haematology Policlinic]'''
 
* '''[https://www.regionaalhaigla.ee/en/radiotherapy-centre Radiotherapy Centre]'''
 
== [[Learning Resources]] ==
 
=== [https://www.regionaalhaigla.ee/et/patsiendikool Patient School] ===
 
'''Content Type:''' E-courses and lectures.
 
'''Target Audience:''' For everyone.
 
=== [https://onkoloogiakeskus.ee/rinnakabinet "Chest Cabinet"] ===
 
'''Content Type:''' Local support for concerns on breast cancer.
 
'''Target Audience:''' Women of all ages.
 
=== [https://onkoloogiakeskus.ee/lahedasele Learning Resources for Relatives and Caretakers] ===
 
'''Content Type:''' Guides and counseling appointment information.
 
'''Target Audience:''' Patients, Relatives and Caretakers.
 
=== Other Learning Materials ===
 
* '''[https://www.regionaalhaigla.ee/en/information-materials Information materials]'''
 
* '''[https://www.regionaalhaigla.ee/en/application-and-issue-medical-records-and-radiological-examination-discs Issue of documents]'''
 
* '''[https://www.regionaalhaigla.ee/en/processing-personal-data Processing of personal data]'''
 
* '''[https://www.regionaalhaigla.ee/en/issuance-death-certificate Issuance of a death certificate]'''
<!--
== [[Novel Therapies and Diagnostic Methods]] ==
-->
 
== [[Cancer-related Patient Associations]] ==
 
=== [https://www.regionaalhaigla.ee/et/patsiendinoukoda Patient Advisory Council] ===
 
'''Primary Purpose:''' To ensure the interests of the patient are being taken into account when making decisions and designing services, and that the patient has an active role in the treatment process.
 
'''Members:''' Estonian Rheumatism Association;
Avitus NGO;
Estonian Inflammatory Bowel Disease Society NGO;
Estonian Celiac Society;
Estonian Psoriasis Association;
Estonian Hemophilia Society;
Estonian Chamber of Disabled People;
Tallinn Chamber of Disabled People;
Saaremaa Cancer Society;
Läänemaa Cancer Association;
Estonian Stroke Patients Society.

Latest revision as of 12:34, 6 December 2025

forresearchers forpatients forproviders forpolicymakers estoniacountry isCancerCenter Go back to Cancer Centers list.

Trials[edit | edit source]

Experts[edit | edit source]

Learning Resources[edit | edit source]

Trainings: Professional Training[edit | edit source]

Novel Therapies and Diagnostic Methods[edit | edit source]

Cancer-related Patient Associations and Resources[edit | edit source]

Resource: Learning Resources for Relatives and Caretakers[edit | edit source]

Resource: Trials Information for Patients[edit | edit source]

Service: Chemotherapy Counseling[edit | edit source]

Service: Palliative Care Nurse Advisor[edit | edit source]

Service: Tobacco Cessation Counseling Office[edit | edit source]


hasCoordinates::59.398689, 24.701547 hasClinicalTrial::Trials_(North_Estonia_Medical_Centre)|Trials hasExperts::Experts_(North_Estonia_Medical_Centre)|Experts hasTraining::Trainings:_Professional_Training_(North_Estonia_Medical_Centre)|Trainings: Professional Training hasHospitalCapacityInfo::Novel_Therapies_and_Diagnostic_Methods_(North_Estonia_Medical_Centre)|Novel Therapies and Diagnostic Methods hasPatientResource::Resource:_Learning_Resources_for_Relatives_and_Caretakers_(North_Estonia_Medical_Centre)|Resource: Learning Resources for Relatives and Caretakers hasPatientResource::Resource:_Trials_Information_for_Patients_(North_Estonia_Medical_Centre)|Resource: Trials Information for Patients hasPatientResource::Service:_Palliative_Care_Nurse_Advisor_(North_Estonia_Medical_Centre)|Service: Palliative Care Nurse Advisor hasPatientResource::Service:_Tobacco_Cessation_Counseling_Office_(North_Estonia_Medical_Centre)|Service: Tobacco Cessation Counseling Office hasCancerType::C00-D48: All neoplasms hasCancerType::C00-C97: All cancer types hasCancerType::C00-C14: Mouth/throat cancers hasCancerType::C15-C26: Digestive system cancers hasCancerType::C30-C39: Lung/chest cancers hasCancerType::C40-C41: Bone cancers hasCancerType::C43-C44: Skin cancers/melanoma hasCancerType::C45-C49: Soft tissue cancer hasCancerType::C50: Breast cancer hasCancerType::C51-C58: Female genitalia cancers hasCancerType::C60-C63: Male genitalia cancer hasCancerType::C64-C68: Urinary system cancers hasCancerType::C69-C72: Eye and brain cancer hasCancerType::C73-C75: Thyroid and other gland cancers hasCancerType::C76-C80: Cancers of unknown or unspecified areas hasCancerType::C81-C96: Cancers of the blood and immune system hasCancerType::C97-C97: Cancers in multiple locations from the start hasCancerType::D00-D09: Early-stage cancers not yet spread hasCancerType::D10-D36: Benign tumour hasCancerType::D37-D48: Growths of uncertain nature hasCancerType::unknown

Retrieved from "https://wiki.beaconcancer.org/index.php?title=North_Estonia_Medical_Centre&oldid=32634"
Powered by MediaWiki
Powered by Semantic MediaWiki